Teclistamab in relapsed and refractory multiple myeloma: patients characteristics from post marketing acces (acces precoce) in France

被引：0
|
作者：
Harel, Stephanie [1 ]
de Colella, Jean-Marc Schiano [2 ]
Sonntag, Cecile [3 ]
Cazaubiel, Titouan [4 ]
Garderet, Laurent [5 ]
Bouillie, Sylvie [6 ]
Javelot, Matthieu [7 ]
Vernet, Sophie [7 ]
Perrot, Aurore [8 ]
机构：
[1] St Louis Hosp, Immunohematol Dept, AP HP, Paris, France
[2] AMU, Inst Paoli Calmettes, CRCM, Marseille, France
[3] ICANS, Dept Hematol, Strasbourg, France
[4] CHU Bordeaux, Bordeaux, France
[5] Hop St Antoine, Serv Hematol & Therapie Cellulaire, AP HP, Paris, France
[6] Janssen Cilag France, Issy Les Moulineaux, France
[7] Med Affair Janssen Cilag France, Issy Les Moulineaux, France
[8] Inst Univ Canc Toulouse Oncopole, Toulouse, France
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-014
引用
收藏
页码：S40 / S41
页数：2
相关论文
共 50 条
  • [1] Teclistamab in Relapsed or Refractory Multiple Myeloma
    Hindie, Elif
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (18): : 1721 - 1723
  • [2] Teclistamab in Relapsed or Refractory Multiple Myeloma
    Moreau, Philippe
    Garfall, Alfred L.
    van de Donk, Niels W. C. J.
    Nahi, Hareth
    San-Miguel, Jesus F.
    Oriol, Albert
    Nooka, Ajay K.
    Martin, Thomas
    Rosinol, Laura
    Chari, Ajai
    Karlin, Lionel
    Benboubker, Lotfi
    Mateos, Maria-Victoria
    Bahlis, Nizar
    Popat, Rakesh
    Besemer, Britta
    Martinez-Lopez, Joaquin
    Sidana, Surbhi
    Delforge, Michel
    Pei, Lixia
    Trancucci, Danielle
    Verona, Raluca
    Girgis, Suzette
    Lin, Shun X. W.
    Olyslager, Yunsi
    Jaffe, Mindy
    Uhlar, Clarissa
    Stephenson, Tara
    Van Rampelbergh, Rian
    Banerjee, Arnob
    Goldberg, Jenna D.
    Kobos, Rachel
    Krishnan, Amrita
    Usmani, Saad Z.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (06): : 495 - 505
  • [3] Ambulatory teclistamab administration in patients with relapsed/refractory multiple myeloma
    Tabbara, Nadeem
    Singel, Michael
    Allen, Natalie
    Mooney, Kathy
    Shedeck, Audra
    Zukas, Amber
    Campion, Kate
    Sollenberger, Callan
    Gocke, Christian Burris
    Ali, Syed Abbas
    Huff, Carol Ann
    Imus, Philip H.
    Waheed, Sarah
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Teclistamab in Relapsed Refractory Multiple Myeloma Patients on Dialysis: A French Experience
    Lachenal, Florence
    Lebreton, Pierre
    Bouillie, Sylvie
    Matteo, Gian
    Aftisse, Hassina
    Pascal, Laurent
    Montes, Lydia
    Macro, Margaret
    Vignon, Marguerite
    Harel, Stephanie
    Fernandez, Mariana
    Louni, Chanaz
    Huart, Antoine
    Perrot, Aurore
    BLOOD, 2023, 142
  • [5] Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma
    James A. Davis
    Jordan Snyder
    Mikhaila Rice
    Donald C. Moore
    Christopher Cahoon
    Kelley Julian
    Charlotte B. Wagner
    Katelynn Granger
    Kimberly M. Green
    Shebli Atrash
    Hailey Hill
    Jessica McElwee
    Grace Elsey
    Jack Khouri
    Joslyn Rudoni
    Zahra Mahmoudjafari
    Victoria R. Nachar
    Blood Cancer Journal, 15 (1)
  • [6] Post-marketing surveillance of carfilzomib in Japanese patients with relapsed or refractory multiple myeloma
    Kawasaki, Akira
    Murakami, Hirokazu
    Chou, Takaaki
    Matsushita, Masaru
    Kizaki, Masahiro
    FUTURE ONCOLOGY, 2022, 18 (24) : 2661 - 2674
  • [7] Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma
    Girgis, Suzette
    Lin, Shun Xin Wang
    Pillarisetti, Kodandaram
    Verona, Raluca
    Vieyra, Diego
    Casneuf, Tineke
    Fink, Damien
    Miao, Xin
    Chen, Yang
    Stephenson, Tara
    Banerjee, Arnob
    Hilder, Brandi W.
    Russell, Jeffery
    Infante, Jeffrey
    Elsayed, Yusri
    Smit, Jennifer
    Goldberg, Jenna D.
    BLOOD ADVANCES, 2023, 7 (04) : 644 - 648
  • [8] Real World Evaluation of Teclistamab: A Focus on Infections in Patients With Relapsed Refractory Multiple Myeloma (RRMM)
    Asoori, Sireesha
    Martin, Thomas
    Wolf, Jeffrey
    Chung, Alfred
    Arora, Shagun
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S536 - S537
  • [9] Safety and Efficacy of Teclistamab in Patients with Relapsed/ Refractory Multiple Myeloma: A Real-World Experience
    Dima, Danai
    Davis, James A.
    Ahmed, Nausheen
    Jia, Xuefei
    Sannareddy, Aishwarya
    Shaikh, Hira
    Shune, Leyla
    Kaur, Gurbakhash
    Khouri, Jack
    Afrough, Aimaz
    Strouse, Christopher
    Lochner, Jonathan
    Mahmoudjafari, Zahra
    Raza, Shahzad
    Valent, Jason
    Anderson Jr, Larry D.
    Anwer, Faiz
    Abdallah, Al-Ola
    Hashmi, Hamza
    TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (03): : 308.e1 - 308.e13
  • [10] Real World Evaluation of Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma (RRMM)
    Maringanti, Sireesha Asoori
    Lin, Yi
    Estritis, Stathis
    Martinez-Lopez, Joaquin
    Bansal, Radhika
    Fotiou, Despina
    Corona, Magdalena
    Chhabra, Saurabh
    Brunaldi, Larissa
    Corraes, Andre De Menezes Silva
    Parrondo, Ricardo
    Kapoor, Prashant
    Ailawadhi, Sikander
    Mas, Reyes
    Tamayo, Andrea
    Dimopoulos, Meletios
    Durie, Brian
    Martin, Thomas
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S506 - S507
12345